BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3813752)

  • 1. Treatment of cancer-associated hypercalcemia with cisplatin.
    Lad TE; Mishoulam HM; Shevrin DH; Kukla LJ; Abramson EC; Kukreja SC
    Arch Intern Med; 1987 Feb; 147(2):329-32. PubMed ID: 3813752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
    Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
    Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study.
    Flores JF; Singer FR; Rude RK
    Miner Electrolyte Metab; 1991; 17(6):390-5. PubMed ID: 1823390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
    McMahan J; Linneman T
    Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and management of severe hypercalcemia.
    Nussbaum SR
    Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment for the electrolytic disorders in cancer patients].
    Shibata H
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2330-3. PubMed ID: 19098400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous etidronate in the management of malignant hypercalcemia.
    Ryzen E; Martodam RR; Troxell M; Benson A; Paterson A; Shepard K; Hicks R
    Arch Intern Med; 1985 Mar; 145(3):449-52. PubMed ID: 3919667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
    Sekine M; Takami H
    Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
    Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
    Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypercalcemia of malignancy in the palliative care patient: a treatment strategy.
    Kovacs CS; MacDonald SM; Chik CL; Bruera E
    J Pain Symptom Manage; 1995 Apr; 10(3):224-32. PubMed ID: 7543127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical treatment of malignant hypercalcemia].
    Eto S; Nakano Y; Okada Y
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How to treat tumor-induced hypercalcemia].
    Body JJ
    Rev Prat; 2003 Dec; 53(19):2128-35. PubMed ID: 15008469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cis-platinum treatment for malignancy-associated humoral hypercalcemia in an athymic mouse model.
    Kukla LJ; Abramson EC; McGuire WP; Shevrin DH; Lad T; Kukreja SC
    Calcif Tissue Int; 1984 Sep; 36(5):559-62. PubMed ID: 6441629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypercalcemia of malignancy--new insights into an old syndrome.
    Esbrit P
    Clin Lab; 2001; 47(1-2):67-71. PubMed ID: 11214225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of tumor-induced hypercalcemia: a solved problem?
    Body JJ; Mancini I
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):241-6. PubMed ID: 12722883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer.
    Yoneda T; Williams P; Rhine C; Boyce BF; Dunstan C; Mundy GR
    Cancer Res; 1995 May; 55(9):1989-93. PubMed ID: 7728770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
    Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
    J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Simple treatment of tumor-induced hypercalcemia: i.v. aminohydroxypropylidene biphosphonate].
    Portmann L; Häfliger JM; Bill G; Burckhardt P
    Schweiz Med Wochenschr; 1983 Dec; 113(51):1960-3. PubMed ID: 6318306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.